Lantern Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview

Lantern Pharma

17/03/2023 20:44

* Lantern Pharma Inc  LTRN.OQ   LTRN.O  is expected to show
no
change in quarterly revenue when it reports  results on March
20. 
    * 
    * ​Refinitiv's mean analyst estimate for Lantern Pharma Inc
is for
a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lantern
Pharma
Inc is $13​, above​ its last closing price of $4.92. ​​​

This summary was machine generated March 17 at 20:44 GMT.  All
figures in US dollars  unless otherwise stated